

Headquarters: Munich, Germany
Product: deepeye® TPS — AI therapy-assistant for retinal diseases (nAMD)
Regulatory status: CE‑marked (Class IIa) under EU MDR
Founded / incorporated: 2021
Team size (public profile): Approximately 11 employees
Ophthalmology — retinal disease therapy planning (neovascular AMD)
2021
Medtech / Healthtech
Public profiles report a single disclosed Seed round with multiple (approx. 4) investors.
“Seed round led by YZR Capital with additional investors including Springboard Health Angels and Bayern Kapital”
| Company |
|---|
What we are doing
Our mission is to prevent vision loss and ultimately blindness by developing AI software that assists eye doctors in therapy planning for their patients. We use computer vision deep learning models(AI) trained on thousands of cases and millions of images to identify and predict disease progression. The decision support algorithm targets popular eye diseases like Age-related Macular Degeneration (AMD, 7.5mio affected in Germany alone).
What we are looking for
Your must-haves
Your nice-to-haves
What we offer
Reach out to us with information about your availability, salary expectations and a link to your conclusive profile (GitHub, LinkedIn, CV). Please share with us why you want to help us in preventing blindness with AI.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week